×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
Yahoo Finance
CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trialYONKERS, N.Y., Oct. 16,...
6 months ago
ContraFect submits IND for novel intravenous antibiotic
CIDRAP
Novel mechanism of action. In July 2020, ContraFect was awarded a grant by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical...
7 months ago
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
The Globe and Mail
Detailed price information for Contrafect (CFRX) from The Globe and Mail including charting and trades.
6 days ago
ContraFect Corporation Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase ...
The Globe and Mail
YONKERS, N.Y., March 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on...
6 days ago
Why ContraFect Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket - Amphenol (N
Benzinga
shares jumped 30% to $0.7398 in pre-market trading after the company reported FDA clearance of CF-370 IND application to proceed with Phase 1...
6 months ago
ContraFect halts phase 3 after antimicrobial fails futility test against MRSA
Fierce Biotech
ContraFect halts phase 3 after antimicrobial fails futility test against MRSA ... After keeping investors waiting for months, ContraFect has...
21 months ago
ContraFect Corporation Prices Public Offering of Common Stock
The Globe and Mail
YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and...
6 days ago
Why Is ContraFect (CFRX) Stock Down 80% Today?
InvestorPlace
A Phase 3 trial of ContraFect's treatment for antibiotic-resistant infections has been stopped, and CFRX stock is plunging.
21 months ago
Contrafect Corporation CFRX is pretty much bust so why d the stock jump 154%?
Dhaka Tribune
Back in July last year the Contrafect trial was stopped by the Data Board (DSMB) on the basis that the results being shown were below the “...
12 months ago
ContraFect begins Phase Ib/II clinical trial of exebacase
Clinical Trials Arena
ContraFect has commenced a Phase Ib/II clinical trial of exebacase in patients with chronic prosthetic joint infections (PJI) of the knee.
12 months ago